Viatar CTC Solutions to Present at 8th Annual LD Micro Main Event Conference
/EINPresswire.com/ -- LOWELL, MA -- (Marketwired) -- 11/30/15 -- Viatar CTC Solutions, Inc. (OTCQB: VRTT), a medical technology company focused on the treatment of patients with metastatic cancer, today announced that Ilan Reich, Chairman and Chief Executive Officer, will present a corporate overview at the 8th Annual LD Micro Main Event being held on December 1-3, 2015 at the Luxe Sunset Hotel, Los Angeles, CA.
Mr. Reich will present on Thursday December 3, 2015 at 1:00 pm PT and will be available for one-on-one meetings on December 2-3, 2015.
About Viatar CTC Solutions
Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells from whole blood using label-free cross-flow filtration. Pending regulatory approval targeted for 2016, it will be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate and gastric cancers. This proprietary technology also powers the company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives.
For More Information:
For Viatar CTC Solutions:
Ilan Reich
Chairman& CEO
ilan.reich@viatarctcsolutions.com
Investor Contacts:
Stephanie Prince
PCG Advisory Group
646.762.4518
Sprince@pcgadvisory.com
Dave Gentry
RedChip Companies
407-644-4256, ext. 104
dave@redchip.com
Media Contact:
Sean Leous
PCG Advisory Group
646.863.8998
sleous@pcgadvisory.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
